Abdelhafiz D, Kilborn S, Bukhari M (јун 2021). „The role of 14-3-3 η as a biomarker in rheumatoid arthritis”. Rheumatology and Immunology Research. 2 (2): 87—90. doi:10.2478/rir-2021-0012.CS1 одржавање: Формат датума (веза)
Fraenkel, L.; Bathon, J. M.; England, B. R.; et al. (јул 2021). „2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.”. Arthritis Care & Research (Hoboken). 73 (7): 924—939. doi:10.1002/acr.24596.CS1 одржавање: Формат датума (веза)
Mori, Shunsuke; Urata, Yukitomo; Yoshitama, Tamami; Ueki, Yukitaka (2021). „Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis”. RMD Open. 7 (2): e001601. PMID33958440. doi:10.1136/rmdopen-2021-001601.
Fraenkel, L.; Bathon, J. M.; England, B. R.; et al. (2021). „2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis”. Arthritis Care & Research (Hoboken). 73 (7): 924—939. PMID34101387.
Mori, Shunsuke; Urata, Yukitomo; Yoshitama, Tamami; Ueki, Yukitaka (2021). „Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis”. RMD Open. 7 (2): e001601. PMID33958440. doi:10.1136/rmdopen-2021-001601.
semanticscholar.org
api.semanticscholar.org
van Venrooij WJ, van Beers JJ, Pruijn GJ (јун 2011). „Anti-CCP antibodies: the past, the present and the future”. Nature Reviews. Rheumatology. 7 (7): 391—398. PMID21647203. S2CID11858403. doi:10.1038/nrrheum.2011.76.CS1 одржавање: Формат датума (веза)